6810.TWO Bio Preventive Medicine Corp.
- Market cap
- TWD 999M
- P/E
- -
- P/B
- 4.07x
- ROE
- -32.5%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Dec 2025.
Is 6810.TWO undervalued?
Graham numberThe Graham number of Bio Preventive Medicine Corp. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Bio Preventive Medicine Corp. fundamental analysis
No fundamental analysis for Bio Preventive Medicine Corp. yet.
Bio Preventive Medicine Corp. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Bio Preventive Medicine Corp.
Bio Preventive Medicine Corp., a clinical-staged biotech company, focusing on early detection and prevention of diseases. The company offers solutions in prevention, screening, and monitoring chronic diseases and cancers management. It also provides DNlite test, a series of patented and clinically validated non-invasive urine test for monitoring the progression of diabetic nephropathy, including DNlite-IVD103 and DNlite-DN_Score. Bio Preventive Medicine Corp. was founded in …
Full company profileBio Preventive Medicine Corp. financial statements
Bio Preventive Medicine Corp. annual financial statements (TWD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Income Statement | |||||||
| Revenue | - | - | 872K | 2.18M | 1.21M | 12.3M | 2.63M |
| Gross Profit | - | -21.2M | 773K | 1.95M | -7.16M | 11.9M | 2.30M |
| Operating Income | -72.1M | -65.1M | -67.0M | -70.8M | -72.6M | -85.8M | -101M |
| EBITDA | -51.9M | -43.2M | -45.6M | -53.8M | -62.3M | -76.6M | -90.0M |
| Net Income | - | -64.8M | -67.2M | -70.9M | -73.3M | -87.6M | -99.8M |
| EPS | - | -2.19 | -2.18 | -2.24 | -2.16 | -2.47 | -2.02 |
| Balance Sheet | |||||||
| Total Assets | - | 221M | 153M | 273M | 265M | 530M | 425M |
| Total Liabilities | - | 19.7M | 14.9M | 133M | 125M | 123M | 118M |
| Shareholders' Equity | - | 202M | 138M | 141M | 140M | 407M | 307M |
| Cash & Short-term Investments | - | 150M | 98.4M | 81.9M | 81.6M | 353M | 251M |
| Total Debt | - | 12.7M | 5.74M | 122M | 113M | 107M | - |
| Cash Flow | |||||||
| Operating Cash Flow | -40.8M | -46.2M | -44.8M | -54.6M | -62.9M | -67.0M | -94.7M |
| Capital Expenditure | 4.37M | 277K | 3.15M | 153M | 1.76M | 615K | 1.93M |
| Free Cash Flow | -45.2M | -46.5M | -48.0M | -207M | -65.7M | -67.6M | -96.7M |
| Ratios | |||||||
| ROE | - | -32.1% | -48.7% | -50.5% | -52.4% | -21.5% | -32.5% |
| ROA | - | -29.3% | -44.0% | -26.0% | -27.7% | -16.5% | -23.5% |
| Net Profit Margin | - | - | -7,709.5% | -3,258.6% | -6,066.6% | -712.0% | -3,800.8% |
| Debt to Equity | - | 0.06x | 0.04x | 0.87x | 0.81x | 0.26x | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Bio Preventive Medicine Corp. dividends
Bio Preventive Medicine Corp. has not paid dividends in the last 7 fiscal years.
Who owns Bio Preventive Medicine Corp.
Ownership data of Bio Preventive Medicine Corp. is not available yet.
Bio Preventive Medicine Corp. company profile
- Company name
- Bio Preventive Medicine Corp.
- Ticker
- 6810.TWO
- ISIN
- TW0006810005
- Exchange
- Taiwan OTC Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Fiscal year end
- December
- Address
- No.18, Taiyuan Street, Zhubei, Taiwan, 302
- Phone
- 886 3 560 1816
- Website
- bpmbiotech.com
About Bio Preventive Medicine Corp.
Bio Preventive Medicine Corp., a clinical-staged biotech company, focusing on early detection and prevention of diseases. The company offers solutions in prevention, screening, and monitoring chronic diseases and cancers management. It also provides DNlite test, a series of patented and clinically validated non-invasive urine test for monitoring the progression of diabetic nephropathy, including DNlite-IVD103 and DNlite-DN_Score. Bio Preventive Medicine Corp. was founded in 2014 and is headquartered in Zhubei, Taiwan.